CryoPort (NASDAQ:CYRX) Releases Earnings Results, Beats Estimates By $0.02 EPS

CryoPort (NASDAQ:CYRX) posted its earnings results on Thursday. The consumer goods maker reported ($0.05) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.02, reports. CryoPort had a negative return on equity of 17.32% and a negative net margin of 35.71%. The company had revenue of $9.58 million for the quarter, compared to analyst estimates of $9.49 million. During the same quarter last year, the company earned ($0.07) earnings per share. The company’s revenue for the quarter was up 81.1% on a year-over-year basis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Shares of CYRX stock traded down $0.25 during trading hours on Friday, reaching $14.03. The company had a trading volume of 762,100 shares, compared to its average volume of 379,665. The company has a debt-to-equity ratio of 0.17, a current ratio of 17.73 and a quick ratio of 17.68. The business has a fifty day simple moving average of $15.05 and a 200-day simple moving average of $17.84. CryoPort has a 12 month low of $8.28 and a 12 month high of $25.02. The company has a market cap of $526.06 million, a price-to-earnings ratio of -45.26 and a beta of 0.77.

CYRX has been the topic of a number of recent research reports. Svb Leerink restated an “outperform” rating on shares of CryoPort in a report on Monday, July 15th. B. Riley set a $26.00 target price on CryoPort and gave the company a “buy” rating in a report on Friday, July 19th. ValuEngine upgraded CryoPort from a “hold” rating to a “buy” rating in a report on Friday, November 1st. BidaskClub lowered CryoPort from a “sell” rating to a “strong sell” rating in a report on Saturday, October 5th. Finally, Leerink Swann initiated coverage on CryoPort in a report on Monday, July 15th. They issued a “buy” rating and a $24.00 target price on the stock. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $24.00.

CryoPort Company Profile

CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.

Featured Story: What is the yield curve?

Earnings History for CryoPort (NASDAQ:CYRX)

Leave a Reply

Your email address will not be published. Required fields are marked *